137 related articles for article (PubMed ID: 6168426)
21. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
[TBL] [Abstract][Full Text] [Related]
22. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
Bonadonna G; Santoro A; Bonfante V; Valagussa P
Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
[TBL] [Abstract][Full Text] [Related]
23. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure.
Porzig KJ; Portlock CS; Robertson A; Rosenberg SA
Cancer; 1978 May; 41(5):1670-5. PubMed ID: 77180
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin.
Pillai GN; Hagemeister FB; Velasquez WS; Sullivan JA; Johnston DA; Butler JJ; Shullenberger CC
Cancer; 1985 Feb; 55(4):691-7. PubMed ID: 2578302
[TBL] [Abstract][Full Text] [Related]
25. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
26. Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease.
Kurnick JE; White M; Ware DE; Robinson WA
Cancer Chemother Rep; 1975; 59(6):1147-50. PubMed ID: 56989
[TBL] [Abstract][Full Text] [Related]
27. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
28. Vinblastine, bleomycin, and cis-platin as salvage therapy for MOPP treated patients with Hodgkin's lymphoma.
Corder MP; Clamon GH; Wiesenfeld M
Cancer Invest; 1984; 2(3):193-8. PubMed ID: 6203626
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Hodgkin's disease with MOPP chemotherapy: effect of dose and schedule modification on treatment outcome.
Bezwoda WR; Dansey R; Bezwoda MA
Oncology; 1990; 47(1):29-36. PubMed ID: 1689018
[TBL] [Abstract][Full Text] [Related]
30. Prednisone in MOPP chemotherapy for Hodgkin's disease.
Jacobs C; Portlock CS; Rosenberg SA
Br Med J; 1976 Dec; 2(6050):1469-71. PubMed ID: 1000259
[TBL] [Abstract][Full Text] [Related]
31. A Southwest Oncology Group: chemotherapy versus chemotherapy plus radiotherapy in treatment of stage III Hodgkin's disease.
Grozea PN; De Persio EJ; Coltman CA; Fabian CJ; Morrison FS; Gehan EA; Jones SE
Recent Results Cancer Res; 1982; 80():83-91. PubMed ID: 6173904
[TBL] [Abstract][Full Text] [Related]
32. Alternating drug combinations in the treatment of advanced Hodgkin's disease.
Santoro A; Bonadonna G; Bonfante V; Valagussa P
N Engl J Med; 1982 Apr; 306(13):770-5. PubMed ID: 6174865
[TBL] [Abstract][Full Text] [Related]
33. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.
Bonadonna G; Valagussa P; Santoro A
Ann Intern Med; 1986 Jun; 104(6):739-46. PubMed ID: 2422994
[TBL] [Abstract][Full Text] [Related]
34. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
35. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
[TBL] [Abstract][Full Text] [Related]
36. ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy.
Clamon GH; Corder MP
Cancer Treat Rep; 1978 Mar; 62(3):363-7. PubMed ID: 77188
[No Abstract] [Full Text] [Related]
37. Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence.
Khan SP; Gilchrist GS; Arndt CA; Smithson WA; Chen MG; Schomberg PJ; Matsumoto JM; O'Fallon WM
Mayo Clin Proc; 1994 Oct; 69(10):949-54. PubMed ID: 7523802
[TBL] [Abstract][Full Text] [Related]
38. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
[TBL] [Abstract][Full Text] [Related]
40. Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP.
Bloomfield CD; Weiss RB; Fortuny I; Vosika G; Kennedy BJ
Cancer; 1976 Jul; 38(1):42-8. PubMed ID: 947533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
